nasdaq trading, page-17

I see your point Bragg and in a way I agree, but I will be holding through results. That is how confident I feel about this trial result, but even now, they could be speeding the Parkinsons MPAC to the clinic. Same with the brain cancer MPAC, working on the Alzheimer's phase3 and continue hiring staff to that end. I would love to see even a very small phase 2 for plaque negative/plaque positive normal age related memory loss. You don't run the finances dry to achieve a nice exit price for traders prior to results, and please no lengthy delays between the next trial start. .
I think they have been very reasonable with dilution so far.
I don't know if they did sell any stock today, but one of us is going to be peeved:-)
I have been looking at other biotechs with similar quality phase 2 assets and some are way above Prana's market cap, but those cos all have strong cash positions.